Australia regulates healthcare advertising through three overlapping regimes, but one rule stands out and surprises almost every marketer who encounters it: in Australia you may not use testimonials about clinical care in advertising a health service — at all. It is not a disclosure requirement or a consent requirement; it is a prohibition written into the law itself. That single feature, combined with aggressive enforcement by the national regulator and a strict ban on advertising prescription medicines to the public, makes Australian healthcare marketing one of the most tightly controlled in the English-speaking world. This guide walks through the whole framework.
01The Three Regimes
Australian medical advertising is governed by three systems that can all apply to a single ad at once. The Health Practitioner Regulation National Law, administered by AHPRA and the National Boards (including the Medical Board of Australia), governs who may advertise a regulated health service and how. The Therapeutic Goods Act 1989, administered by the TGA, governs the advertising of medicines and medical devices. And the Australian Consumer Law, administered by the ACCC, provides a general misleading-conduct overlay. You have to clear all three.
02Section 133: The Five Prohibitions
The centrepiece is Section 133 of the National Law. It makes it a criminal offence to advertise a regulated health service in a way that does any of five things, and it binds not just practitioners but anyone who advertises a regulated health service — clinics, companies, and the marketers acting for them.
Advertising must not: (1) be false, misleading or deceptive, or likely to be — the broadest limb, which catches exaggeration, omission of material facts, misuse of titles like "specialist" or "surgeon," and any false overall impression even from literally true statements; (2) offer a gift, discount or inducement without stating the terms and conditions; (3) use testimonials or purported testimonials about the service; (4) create an unreasonable expectation of beneficial treatment, such as implying guaranteed or risk-free outcomes; or (5) directly or indirectly encourage the indiscriminate or unnecessary use of health services. Breaching Section 133 is both a prosecutable offence and grounds for AHPRA disciplinary action against the practitioner's registration.
03The Testimonial Ban, Explained
Because the testimonial prohibition trips up so many practices, it is worth understanding precisely. AHPRA defines a testimonial as a recommendation or positive statement about the clinical aspects of a regulated health service. A statement is "clinical" — and therefore banned in advertising — if it references the patient's symptom, their diagnosis or treatment, or the outcome or the practitioner's skill. So "Dr X cured my back pain and I can run again" is a banned clinical testimonial.
What is not a testimonial, and may be used, is comment purely about customer service that does not touch clinical matters — "friendly staff," "easy to book," "clean clinic," "ran on time."
The nuance that matters most in practice concerns third-party reviews. A practitioner is not responsible for removing unsolicited clinical reviews that patients post on platforms the practitioner does not control, such as Google or RateMDs — those are not the practitioner's advertising. But the moment a practitioner engages with such a review — sharing it, re-posting it, linking to it, embedding it, "liking" it, or inviting it onto a page they control — it becomes advertising they are responsible for, and it breaches Section 133. AHPRA's guidance is therefore to disable reviews and testimonials on your own website and social media pages so that clinical testimonials cannot appear on a platform you control. (There has been reform pressure to repeal the testimonial ban, but as of writing that repeal has not commenced and the ban remains fully in force — an area worth re-checking.)
04The TGA: No Advertising Prescription Medicines to the Public
The second regime bans direct-to-consumer advertising of prescription medicines. Under the Therapeutic Goods Act and the Advertising Code, prescription (Schedule 4) medicines, controlled drugs (Schedule 8), most pharmacist-only medicines, and any product not on the Australian Register of Therapeutic Goods may not be advertised to the public. The TGA specifically flags weight-loss injections (GLP-1s), medicinal cannabis, and nicotine vaping products as prescription-only and off-limits for consumer advertising. You cannot dodge the ban with an "ask your doctor" disclaimer. Advertising directed only to health professionals is separately permitted and regulated, and information a doctor gives directly to their own patient is exempt. The Code also restricts references to serious diseases and requires care with endorsements and influencer content for therapeutic goods.
05Cosmetic Procedures: The Post-2023 Crackdown
Following a national review of the cosmetic surgery sector, the Medical Board's advertising guidelines for cosmetic surgery took effect on 1 July 2023 and tightened the rules considerably. Before-and-after images must not be edited or enhanced — no filters, no retouching that hides scarring or bruising — and any outcome image must carry a prominent warning that results are patient-specific. The testimonial ban applies in full, so cosmetic patient stories are out. Images of under-18s must not be used, advertising must not target under-18s, and cosmetic content on social media should be labelled adult content. Practitioners must not exploit body-image vulnerability, must not imply body image will be "improved," and must not use algorithms to push content at vulnerable groups; even excessive posting frequency is flagged as normalising surgery. In September 2025 AHPRA extended comparable safeguards to higher-risk non-surgical cosmetic procedures such as injectables.
06The Consumer Law Overlay
On top of all that, the Australian Consumer Law applies because providing a health service is conduct "in trade or commerce." Section 18 prohibits misleading or deceptive conduct — no intent required, judged on the dominant impression created — and Section 29 prohibits specific false representations and is a civil-penalty provision the ACCC can enforce with significant fines. The same ad can breach both Section 133 and the ACL.
07The Penalties
Penalties under the National Law for advertising offences were substantially increased through a 2022 amendment package, now in force nationally: the figures commonly cited are up to around sixty thousand dollars per offence for an individual and double that for a body corporate — and critically, the penalty is per offence, so a campaign of multiple non-compliant posts multiplies the exposure. On top of the fines sits the disciplinary track: a breach is "unsatisfactory professional conduct," exposing the practitioner to cautions, conditions, reprimand, suspension, or cancellation of registration. The TGA carries its own heavy penalties — criminal offences with imprisonment and very large fines where advertising risks harm, plus substantial civil penalties and infringement notices (the exact dollar figures track the Commonwealth penalty unit, which is indexed periodically, so current values should be confirmed). The ACCC can pursue significant civil penalties under the consumer law. And AHPRA has, since 2023, deployed auditing technology to proactively scan websites and social media for banned testimonials and misleading cosmetic claims, with its CEO publicly warning practitioners that profit-over-care marketing will be acted on.
08A Compliant Australian Marketing Playbook
Build your marketing on factual, verifiable information and education rather than persuasion. Remove every clinical testimonial from anything you control, and disable reviews and comments on your own pages so they cannot appear there; let independent third-party reviews live on platforms you do not touch, and never engage with the clinical ones. State terms and conditions on any offer, and avoid inducements that could drive unnecessary care. Never advertise a prescription medicine to the public — sell the consultation, not the drug. For cosmetic work, follow the stricter 2023 and 2025 rules to the letter: unedited images with warnings, no under-18 targeting, no body-image exploitation. And remember the penalties are per offence and the regulator is actively scanning — so compliance has to be built into every post, not retrofitted after a complaint.
This is general educational information, not legal advice. Australian medical advertising law spans the National Law (Section 133), the TGA, and the ACCC; penalty figures are indexed or periodically amended, the testimonial ban remains under reform pressure, and the National Law is applied separately in each state and territory. Confirm the current position with AHPRA, the TGA, and a qualified Australian healthcare lawyer before acting.
